Free Trial

IM Cannabis (IMCC) Competitors

IM Cannabis logo
$3.30 +0.34 (+11.49%)
Closing price 07/7/2025 03:59 PM Eastern
Extended Trading
$3.28 -0.01 (-0.45%)
As of 07/7/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMCC vs. CVKD, CALC, OVID, GBIO, CMMB, ELEV, FGEN, DARE, FNCH, and RLMD

Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Cadrenal Therapeutics (CVKD), CalciMedica (CALC), Ovid Therapeutics (OVID), Generation Bio (GBIO), Chemomab Therapeutics (CMMB), Elevation Oncology (ELEV), FibroGen (FGEN), Dare Bioscience (DARE), Finch Therapeutics Group (FNCH), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.

IM Cannabis vs. Its Competitors

IM Cannabis (NASDAQ:IMCC) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 48.6% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

IM Cannabis has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

In the previous week, IM Cannabis had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for Cadrenal Therapeutics. IM Cannabis' average media sentiment score of 0.00 equaled Cadrenal Therapeutics'average media sentiment score.

Company Overall Sentiment
IM Cannabis Neutral
Cadrenal Therapeutics Neutral

Cadrenal Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 147.10%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cadrenal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cadrenal Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -9.10%. IM Cannabis' return on equity of -122.96% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-9.10% -122.96% -11.69%
Cadrenal Therapeutics N/A -244.94%-181.94%

IM Cannabis has higher revenue and earnings than Cadrenal Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.44M0.34-$7.72M-$0.64-5.16
Cadrenal TherapeuticsN/AN/A-$10.65M-$9.26-1.40

Summary

IM Cannabis and Cadrenal Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCC vs. The Competition

MetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$11.97M$10.52B$5.52B$9.02B
Dividend YieldN/A2.07%5.24%4.08%
P/E Ratio-5.1616.9127.1920.04
Price / Sales0.3428.87395.22100.83
Price / CashN/A23.9726.2128.59
Price / Book3.203.637.925.55
Net Income-$7.72M$235.43M$3.17B$248.49M
7 Day Performance22.22%-0.32%1.79%4.87%
1 Month Performance19.57%-0.33%1.28%6.63%
1 Year Performance52.78%-10.48%33.32%20.38%

IM Cannabis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCC
IM Cannabis
0.334 of 5 stars
$3.30
+11.5%
N/A+31.3%$11.97M$39.44M-5.16340
CVKD
Cadrenal Therapeutics
2.6888 of 5 stars
$11.59
-3.8%
$32.00
+176.1%
N/A$22.83MN/A-1.254Positive News
Gap Up
CALC
CalciMedica
3.2841 of 5 stars
$1.63
+1.9%
$18.00
+1,004.3%
-62.0%$22.77MN/A-1.0430Positive News
Gap Up
OVID
Ovid Therapeutics
4.2033 of 5 stars
$0.32
-3.3%
$3.13
+879.6%
-49.8%$22.76M$570K-0.9160Gap Up
High Trading Volume
GBIO
Generation Bio
2.9214 of 5 stars
$0.33
+4.0%
$7.33
+2,102.2%
-84.7%$22.32M$19.89M-0.31150News Coverage
Gap Down
CMMB
Chemomab Therapeutics
2.8749 of 5 stars
$1.18
+1.7%
$8.50
+620.3%
+16.8%$22.26MN/A-1.5520
ELEV
Elevation Oncology
1.9004 of 5 stars
$0.37
+0.2%
$3.39
+820.0%
-86.7%$21.79MN/A-0.4540
FGEN
FibroGen
4.7005 of 5 stars
$5.33
+0.6%
$250.00
+4,590.4%
-70.2%$21.53M$29.62M-2.13570Positive News
DARE
Dare Bioscience
1.5673 of 5 stars
$2.41
+0.6%
$12.00
+399.0%
-23.8%$21.28M$10K-14.1530
FNCH
Finch Therapeutics Group
1.0469 of 5 stars
$13.20
flat
N/A+923.6%$21.20M$110K-1.50190Positive News
RLMD
Relmada Therapeutics
4.5971 of 5 stars
$0.63
+5.6%
$5.00
+688.6%
-79.8%$21.04MN/A-0.2510Gap Down

Related Companies and Tools


This page (NASDAQ:IMCC) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners